Volume 99, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Vaccine immunogenicity and clinical efficacy are often assessed by the measure of serum-neutralizing antibodies. The present gold standard for detecting neutralizing antibodies against many viruses, including dengue, is the plaque/focus reduction neutralization test (P/FRNT). The FRNT is a cell-based assay that inherits high variability, resulting in poor precision and has lengthy turnaround times. The virus reduction neutralization test (VRNT) is a high-throughput alternative to the standard low-throughput and laborious FRNT. The VRNT is similar to FRNT using unaltered wild-type virus and immunostaining, yet uses imaging cytometry to count virus-infected cells 1 day post-infection, reducing assay time and increasing overall throughput 15-fold. In addition, the VRNT has lowered variability relative to FRNT, which may be explained in part by the observation that foci overlap alters foci count and titer over time, in the FRNT. The ability to count one infected cell, rather than waiting for overlapping foci to form, ensures accuracy and contributes to the precision (7–25% coefficient of variation) and sensitivity of the VRNT. Results from 81 clinical samples tested in the VRNT and FRNT show a clear positive relationship. During sample testing, a 96-well plate edge effect was noted and the elimination of this edge effect was achieved by a simple plate seeding technique. The VRNT is an improvement to the current neutralization assays for its shortened assay time, increased precision and throughput, and an alternative to the P/FRNT.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO, 2017. Dengue Fact Sheet. Geneva, Switzerland: World Health Organization. [Google Scholar]
  2. Green S, Rothman A, , 2006. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19: 42936. [Google Scholar]
  3. WHO, 2013. Guidelines on the Quality, Safety and Efficacy of Dengue Tetravalent Vaccines (live, attenuated) Technical Report Series. Geneva, Switzerland: World Health Organization. [Google Scholar]
  4. Hadinegoro SR, 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373: 1195206. [Google Scholar]
  5. Godoi IP, 2017. CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. J Comp Eff Res 6: 165180. [Google Scholar]
  6. WHO, 2012. Global Strategy for Dengue Prevention and Control, 2012–2020. Geneva, Switzerland: World Health Organization Press. [Google Scholar]
  7. Durbin AP, 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 40513. [Google Scholar]
  8. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW, , 2013. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 88: 96270. [Google Scholar]
  9. Torresi J, Ebert G, Pellegrini M, , 2017. Vaccines licensed and in clinical trials for the prevention of dengue. Hum Vaccin Immunother 13: 10591072. [Google Scholar]
  10. Saez-Llorens X., Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, Borkowski A, Wallace D, , 2017. Safety and immunogenicity of one versus two doses of Takeda’s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis 17: 615625. [Google Scholar]
  11. L'Azou M, 2016. Symptomatic dengue in children in 10 Asian and Latin American countries. N Engl J Med 374: 11551166. [Google Scholar]
  12. Roehrig JT, Hombach J, Barrett AD, , 2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21: 12332. [Google Scholar]
  13. Tan C, Iglewicz B, , 1999. Measurement-methods comparisons and linear statistical relationship. Technometrics 41: 192201. [Google Scholar]
  14. Lin LI, , 1989. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45: 25568. [Google Scholar]
  15. Salje H, Rodríguez-Barraquer I, Rainwater-Lovett K, Nisalak A, Thaisomboonsuk B, Thomas SJ, Fernandez S, Jarman RG, Yoon IK, Cummings DA, , 2014. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development. PLoS Negl Trop Dis 8: e2952. [Google Scholar]
  16. Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, Lessler J, , 2012. Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. BMC Infect Dis 12: 233. [Google Scholar]
  17. Shan C, Xie X, Ren P, Loeffelholz MJ, Yang Y, Furuya A, Dupuis AP, 2nd Kramer LD, Wong SJ, Shi PY, , 2017. A rapid Zika diagnostic assay to measure neutralizing antibodies in patients. EBioMedicine 17: 157162. [Google Scholar]
  18. Song KY, 2014. A novel reporter system for neutralizing and enhancing antibody assay against dengue virus. BMC Microbiol 14: 44. [Google Scholar]
  19. Yang H, Baker SF, González ME, Topham DJ, Martínez-Sobrido L, Zand M, Holden-Wiltse J, Wu H, , 2016. An improved method for estimating antibody titers in microneutralization assay using green fluorescent protein. J Biopharm Stat 26: 409420. [Google Scholar]
  20. Maistriau M, Carletti T, Zakaria MK, Braga L, Faoro V, Vasileiadis V, Marcello A, , 2016. A method for the detection of virus infectivity in single cells and real time: towards an automated fluorescence neutralization test. Virus Res 237: 16. [Google Scholar]
  21. Lin R, Heeke D, Liu H, Rao E, Marshall JD, Chio V, Cataniag F, Yu L, Zuo F, McCarthy MP, , 2017. Development of a robust, higher throughput green fluorescent protein (GFP)-based epstein-barr virus (EBV) micro-neutralization assay. J Virol Methods 247: 1521. [Google Scholar]

Data & Media loading...

Supplemental table and figure

  • Received : 05 Dec 2017
  • Accepted : 21 Aug 2018
  • Published online : 22 Oct 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error